

PDE10A Antibody (monoclonal) (M02)**Mouse monoclonal antibody raised against a partial recombinant PDE10A.****Catalog # AT3250a****Specification**

PDE10A Antibody (monoclonal) (M02) - Product Information

Application	E
Primary Accession	O9Y233
Other Accession	NM_006661
Reactivity	Human
Host	mouse
Clonality	Monoclonal
Isotype	IgG1 Kappa
Calculated MW	114946

PDE10A Antibody (monoclonal) (M02) - Additional Information**Gene ID** 10846**Other Names**

cAMP and cAMP-inhibited cGMP 3', 5'-cyclic phosphodiesterase 10A, PDE10A

Target/Specificity

PDE10A (NP_006652, 242 a.a. ~ 333 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Dilution

E~~N/A

Format

Clear, colorless solution in phosphate buffered saline, pH 7.2 .

Storage

Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

Precautions

PDE10A Antibody (monoclonal) (M02) is for research use only and not for use in diagnostic or therapeutic procedures.


PDE10A Antibody (monoclonal) (M02) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)

- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

PDE10A Antibody (monoclonal) (M02) - Images



Detection limit for recombinant GST tagged PDE10A is approximately 0.03ng/ml as a capture antibody.

PDE10A Antibody (monoclonal) (M02) - Background

Various cellular responses are regulated by the second messengers cAMP and cGMP. Phosphodiesterases, such as PDE10A, eliminate cAMP- and cGMP-mediated intracellular signaling by hydrolyzing the cyclic nucleotide to the corresponding nucleoside 5-prime monophosphate (Fujishige et al., 2000 [PubMed 10998054]).

PDE10A Antibody (monoclonal) (M02) - References

Analyses of shared genetic factors between asthma and obesity in children. Mel?n E, et al. J Allergy Clin Immunol, 2010 Sep. PMID 20816195. Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086. Interplay of palmitoylation and phosphorylation in the trafficking and localization of phosphodiesterase 10A: implications for the treatment of schizophrenia. Charych EI, et al. J Neurosci, 2010 Jul 7. PMID 20610737. Common variants in FOXP1 are associated with generalized vitiligo. Jin Y, et al. Nat Genet, 2010 Jul. PMID 20526340. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Rose JE, et al. Mol Med, 2010 Jul-Aug. PMID 20379614.